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The majority of the most common hemoglobinopathies, which include sickle cell disease 32 
(SCD) and thalassemia, are not indigenous to Europe but are now becoming prevalent. In 33 
this issue, Cela et al (1) report on the first Spanish National Registry of Hemoglobinopathy, 34 
which provides an opportunity to recognize and address this increasing prevalence. The 35 
authors report important epidemiological and public health outcome data from 715 eligible 36 
patients. Barely 15 years following the first report of a case of SCD in Spain, the average 37 
number of new cases has risen from 1.7 per year before 1996, to 42.2 cases per year in the 38 
5-year period between 2006 and 2010, while those for thalassemia remain relatively 39 
unchanged (0.3 and 3.3, respectively). This reflects the pattern of migration to Spain mainly 40 
from African countries. The main European Union migrant population groups come from 41 
areas with a high prevalence of hemoglobinopathies (countries in the Middle East, North 42 
Africa and Sub-Saharan Africa). However, Italy and Spain receive mainly African immigrants 43 
due to their geographic proximity, while Greece and Central European countries receive 44 
more patients from the Middle East Region (Figure 1). 45 
 46 
A survey of the European Union reported that areas of low incidence such as Sweden and 47 
Spain, have very low awareness of hemoglobinopathies and this leads to under-diagnosis 48 
and lack of access to care for ethnic minority populations (2). Only a few countries – Cyprus, 49 
UK, Belgium, Italy, France and Greece – have national or targeted education campaigns to 50 
raise awareness about hemoglobinopathies. However, with current trends in migration this 51 
situation may change, and historically low prevalence regions will now need to care for 52 
increased number of patients with major hemoglobinopathies. Therefore urgent action may 53 
be required within a short time to meet the challenges and address the opportunities. 54 
 55 
Similar trends in the pattern of hemoglobinopathies were reported in Canada a generation 56 
ago, with a fall in the British population from 60% in 1871 to 45% in 1971, and an increase in 57 
French Canadians from 10 to 30%, leading to a rise in thalassemia prevalence (3). 58 
Furthermore a report from the UK (4) showed a decrease in utilization of prenatal diagnosis 59 
by migrants from Cyprus, and an increase among those from Pakistan and Sub-Saharan 60 
African countries. The current report of a comprehensive National Hemoglobinopathy 61 
Registry in Spain provides further evidence for the need to implement nationwide collection 62 
of data in hemoglobinopathies.  63 
 64 
The benefits of establishing registries have been recognized in many countries. As stated by 65 
Hullihan et al (5) “a comprehensive understanding of the impact of hemoglobinopathies in 66 
the USA is important to public health practitioners, researchers, health insurers, and policy 67 
makers.” In the United Kingdom (UK), the earliest registries for SCD and thalassemia were 68 
developed independently (6, 7). Following the implementation of universal newborn and 69 
linked antenatal screening for hemoglobinopathies in 2004, it became apparent that a full 70 
comprehensive national hemoglobinopathy registry in the UK for both SCD and thalassemia 71 
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was imperative (8). In 2009, the National Hemoglobinopathy Registry was implemented and 72 
by 2013-14 the majority of patient in England had been registered  73 
(http://www.nhr.nhs.uk/wp-content/uploads/2015/10/NHR_AnnualReport_2014.pdf). A 74 
national steering committee made of a multidisciplinary team is responsible for reviewing the 75 
content and governance structure of this registry. This effort is led by the UK Forum on 76 
hemoglobin disorders (http://www.haemoglobin.org.uk/) and two patient user groups: Sickle 77 
Cell Society (http://sicklecellsociety.org/) and UK thalassemia Society (http://www.ukts.org/), 78 
which raise awareness and resources to provide detailed patient information, treatment and 79 
newborn outcomes.  80 
 81 
National hemoglobinopathy registries across Europe will enhance monitoring of changing 82 
demographics, service delivery and patient outcomes. In order to achieve comprehensive 83 
coverage, it is necessary to consider innovative ways to increase patient registration and 84 
accrual into the databases such as inclusion of: 85 
i) Hospital medical records to synchronize with registry data and become a source to 86 
update patient management and outcomes;  87 
ii) Population demographics to include details about ethnicity and heritage, which may 88 
be utilized to establish the target population for screening and intensive 89 
enlightenment through their community organizations and social network; 90 
iii) Insurance data that could also enhance national registries. 91 
  92 
Appropriate funding of registries is a challenge that can be surmounted only through 93 
effective advocacy and engagement of commissioning organizations. The fact that registries 94 
may cost only a fraction of patient care should be an incentive for those commissioning 95 
services and could enable the development of services for patients in affected communities. 96 
 97 
The role of surveillance systems for hemoglobinopathies, such as registries, is significant for 98 
the allocation of resources and public engagement and the data may facilitate policy making 99 
decisions. By providing an overview of the demographic pattern of hemoglobinopathies, they 100 
are essential tools for monitoring patient outcomes. As stated by Cela et al and others, they 101 
also provide an important resource for research. It is reassuring to note the cost of running a 102 
registry is affordable (7), and offers a resource for economic planning for equitable care and 103 
service improvement. The development of national registries needs to be supported by rare 104 
anemia networks such as the pilot European Network on Rare and Congenital Anemias-105 
ENERCA, or the recently established European Network- EuroBloodNet in order to foster 106 
lessons from countries with advanced programmes. Non-European countries, such as those 107 
in the Middle East and Sub-Saharan Africa, where the vast majority of patients live, may 108 
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benefit from such examples of good practice in order to utilize their limited resources 109 
appropriately (9,10). In the long term, we should adopt an approach capable of facilitating 110 
effective collaborations and sharing good practices between countries of high prevalence but 111 
low in resources and those with lower prevalence but well-developed pathways of care. 112 
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Figure 1. Migration to Europe; countries of origin and destination January to November, 152 
2016. Permission to reproduce figure granted by the International Organization of Migration. 153 
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